Corticosteroid treatment in active Crohn's disease

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Crohn's disease management often relies on corticosteroids for flare-ups.
• Systemic steroids offer short-term efficacy but are associated with significant adverse effects.
• Optimal dosing and duration for corticosteroid therapy in Crohn's disease remain undefined.

Purpose of the Study:

• To evaluate the efficacy and tolerance of corticosteroid treatments for Crohn's disease flares.
• To compare oral prednisolone with topical corticosteroids like budesonide.

Main Methods:

• Review of existing literature on corticosteroid treatment for Crohn's disease.
• Analysis of clinical remission rates associated with specific dosing regimens.

Main Results:

• Oral prednisolone at 1 mg/Kg daily for 3-7 weeks resulted in clinical remission in 92% of patients.
• Topical oral corticosteroids, such as budesonide, demonstrate potential for improved patient tolerance.
• Budesonide shows promise in mild to moderate Crohn's disease flares, but further research is needed for severe cases.

Conclusions:

• High-dose oral prednisolone is highly effective for inducing remission in Crohn's disease flares.
• Budesonide represents a potentially better-tolerated alternative, particularly for mild to moderate disease.
• Further investigation is required to clarify budesonide's role in severe Crohn's disease and in combination therapy.